Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 06, 2016 5:02 PM ET


Company Overview of Daiichi Sankyo, Inc.

Company Overview

Daiichi Sankyo, Inc. operates as a research-based pharmaceutical company that discovers, develops, and commercializes pharmaceutical products. It offers olmesartan medoxomil, hydrochlorothiazide, prasugrel, cevimeline HCI, amlodipine, colesevelam HCI, and vemurafenib tablets. The company provides therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma areas. It serves patients, and professional organizations and institutions in the United States and internationally. Daiichi Sankyo, Inc. was formerly known as Sankyo Pharma Inc. and changed its name to Daiichi Sankyo, Inc. in April 2006. The company was founded in 1996 and is based in Parsippany, New...

Two Hilton Court

Suite 2

Parsippany, NJ 07054

United States

Founded in 1996





Key Executives for Daiichi Sankyo, Inc.

Executive Chairman, President, Global Head of Research & Development - Daiichi Sankyo Ltd and Senior Executive Officer of Daiichi Sankyo Ltd
Vice President of Operations
Chief Executive Officer of Daiichi Sankyo Co., Ltd. and President of Daiichi Sankyo Co., Ltd.
President of Commercial Operations
Age: 52
Executive Vice President and Head of Global Business Development
Compensation as of Fiscal Year 2015.

Daiichi Sankyo, Inc. Key Developments

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints

Charleston Laboratories, Inc., and Daiichi Sankyo, Inc. announced that a third Phase 3 clinical trial of CL-108, an opioid-containing formulation, met its primary endpoints. CL-108 is a bi-layered tablet containing 7.5 mg of hydrocodone and 325 mg of acetaminophen uniquely formulated with 12.5 mg of rapid-release promethazine. This novel formulation is being developed as a treatment for moderate to severe pain and the prevention of opioid-induced nausea and vomiting (OINV). This recently completed Phase 3 clinical trial was a randomized, double-blind, placebo- and active-controlled study in over 550 patients in the U.S. who experienced moderate to severe pain after bunionectomy surgery. Results from the study demonstrated significant pain relief and prevention of OINV by CL-108.

Daiichi Sankyo, Inc. Reorganizes U.S. Commercial Operations to Support Upcoming Specialty Pipeline; to Eliminate 1,000 to 1,200 Positions

Daiichi Sankyo, Inc. announced that it will reorganize its U.S. Commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology. Daiichi Sankyo recognizes the macro changes occurring in the U.S. healthcare system that place a greater emphasis on managing the needs of patients with more complex healthcare needs. As part of the reorganization, the Company will reduce expenses, including a reduction in headcount, from its U.S. Commercial operations. The Company expects to eliminate 1,000 to 1,200 positions across the U.S. Commercial function, through voluntary and involuntary displacements as well as eliminating open positions. The eliminated jobs will come from the U.S. Commercial Home Office, located in Parsippany, New Jersey, as well as field-based sales and other positions throughout the country. This reorganization is not focused on U.S.-based R&D functions, which have staff concentrated in Edison, NJ, or its packaging plant in Bethlehem, PA.

Daiichi Sankyo, Inc. Reports Revenue Results for the First Quarter of Fiscal 2016; Revised Revenue Guidance for Fiscal 2016

Daiichi Sankyo, Inc. reported revenue results for the first quarter of fiscal 2016. Revenue was JPY 48.0 billion against JPY 41.6 billion last year. The company revised revenue guidance for fiscal 2016. The company expects revenue of JPY 166.0 billion against previous guidance of JPY 140.0 billion.

Similar Private Companies By Industry

Company Name Region
Forest Research Institute, Inc. United States
Libertas Pharma Inc. United States
Azelon Pharmaceuticals, Inc. United States
Plymouth Pharmaceuticals, Inc. United States
Intellikine LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Daiichi Sankyo, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at